期刊
CURRENT RHEUMATOLOGY REPORTS
卷 14, 期 3, 页码 264-274出版社
SPRINGER
DOI: 10.1007/s11926-012-0246-6
关键词
Idiopathic inflammatory myopathy; Myositis; Biomarkers; Polymyositis; Dermatomyositis; Clinically amyopathic dermatomyositis; Interstitial lung disease; Interstitial pneumonia; NSIP; Antisynthetase antibody; Anti-CADM-140 antibody; Aminoacyl-transfer RNA synthetase; MDA5; IFIH1; HRCT; KL-6; SP-D; Ferritin; Glucocorticoids; Cyclophosphamide; Cyclosporine; Tacrolimus; Rituximab; Treatment
类别
资金
- Japan Society for the Promotion of Science
- Ministry of Health, Labor, and Welfare (Japan)
- Grants-in-Aid for Scientific Research [22659185] Funding Source: KAKEN
Interstitial lung disease (ILD) is the most frequent organ involvement (found in nearly half) of myositis patients, but it reveals various clinical courses and therapeutic responsiveness according to clinical and serological subsets. Autoantibodies, as well as imaging and histopathological studies, are useful for the classification of ILD in myositis and provide useful information for predicting prognosis and determining treatment. Antisynthetase antibodies are correlated with chronic and recurrent ILD, whereas anti-CADM-140 (MDA5/IFIH1) antibodies are a marker of acute progressive ILD in clinically amyopathic dermatomyositis. Serum KL-6, SP-D, and ferritin are useful biomarkers for monitoring the activity and severity of ILD. Regarding treatment, glucocorticoids are the first-line drug, but additional immunomodulating drugs are also used in refractory patients. Cyclophosphamide and calcineurin inhibitors (cyclosporine and tacrolimus) appear to be the key drugs in the treatment of refractory myositis-ILD. Rituximab may become another candidate if these drugs are not effective.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据